These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 15793249)

  • 21. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue.
    Kolterman OG; Gottlieb A; Moyses C; Colburn W
    Diabetes Care; 1995 Aug; 18(8):1179-82. PubMed ID: 7587855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.
    Kovatchev BP; Crean J; McCall A
    Diabetes Technol Ther; 2008 Oct; 10(5):391-6. PubMed ID: 18715216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.
    Edelman SV; Weyer C
    Diabetes Technol Ther; 2002; 4(2):175-89. PubMed ID: 12079621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes.
    Hinshaw L; Schiavon M; Dadlani V; Mallad A; Dalla Man C; Bharucha A; Basu R; Geske JR; Carter RE; Cobelli C; Basu A; Kudva YC
    J Clin Endocrinol Metab; 2016 May; 101(5):1954-62. PubMed ID: 26930181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.
    Galderisi A; Sherr J; VanName M; Carria L; Zgorski M; Tichy E; Weyman K; Cengiz E; Weinzimer S; Tamborlane W
    J Clin Endocrinol Metab; 2018 Mar; 103(3):1088-1094. PubMed ID: 29211871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.
    Pullman J; Darsow T; Frias JP
    Vasc Health Risk Manag; 2006; 2(3):203-12. PubMed ID: 17326327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
    Renukuntla VS; Ramchandani N; Trast J; Cantwell M; Heptulla RA
    J Diabetes Sci Technol; 2014 Sep; 8(5):1011-7. PubMed ID: 25030181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pramlintide acetate.
    McQueen J
    Am J Health Syst Pharm; 2005 Nov; 62(22):2363-72. PubMed ID: 16278328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pramlintide in the treatment of diabetes mellitus.
    Edelman S; Maier H; Wilhelm K
    BioDrugs; 2008; 22(6):375-86. PubMed ID: 18998755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
    Hollander PA; Levy P; Fineman MS; Maggs DG; Shen LZ; Strobel SA; Weyer C; Kolterman OG
    Diabetes Care; 2003 Mar; 26(3):784-90. PubMed ID: 12610038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used.
    King AB
    Endocr Pract; 2009 Apr; 15(3):229-33. PubMed ID: 19364691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.
    Ceriello A; Piconi L; Quagliaro L; Wang Y; Schnabel CA; Ruggles JA; Gloster MA; Maggs DG; Weyer C
    Diabetes Care; 2005 Mar; 28(3):632-7. PubMed ID: 15735200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.
    Weyer C; Maggs DG; Young AA; Kolterman OG
    Curr Pharm Des; 2001 Sep; 7(14):1353-73. PubMed ID: 11472273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
    Weinzimer SA; Sherr JL; Cengiz E; Kim G; Ruiz JL; Carria L; Voskanyan G; Roy A; Tamborlane WV
    Diabetes Care; 2012 Oct; 35(10):1994-9. PubMed ID: 22815298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.
    Ramkissoon CM; Aufderheide B; Bequette BW; Palerm CC
    J Diabetes Sci Technol; 2014 May; 8(3):529-42. PubMed ID: 24876617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
    Edelman S; Garg S; Frias J; Maggs D; Wang Y; Zhang B; Strobel S; Lutz K; Kolterman O
    Diabetes Care; 2006 Oct; 29(10):2189-95. PubMed ID: 17003291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
    Andersen G; Meiffren G; Famulla S; Heise T; Ranson A; Seroussi C; Eloy R; Gaudier M; Charvet R; Chan YP; Soula O; DeVries JH
    Diabetes Obes Metab; 2021 Apr; 23(4):961-970. PubMed ID: 33336850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide.
    Kolterman OG
    Diabet Med; 1997 Jun; 14 Suppl 2():S35-8. PubMed ID: 9212328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
    Whitehouse F; Kruger DF; Fineman M; Shen L; Ruggles JA; Maggs DG; Weyer C; Kolterman OG
    Diabetes Care; 2002 Apr; 25(4):724-30. PubMed ID: 11919132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.